Gilead poaches new pharma development and manufacturing chief from cell therapy 2.0 player
Gilead has raided one of the up-and-coming cell therapy 2.0 biotechs to find its new head of pharma development and manufacturing.
Dan O’Day’s pharma player has recruited Stacey Ma from Sana Biotechnology for the senior executive team. A Genentech vet, Ma has been head of technical operations at Sana, which has just opted to change up its manufacturing building plans in favor of Seattle over their original site in California. Sana CEO Steve Harr had proudly held Ma up as one of the top R&D execs at the company.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.